APOLLO HOSPITALS ENTER. L vs LINCOLN PHARMA LTD

A side-by-side comparison of APOLLO HOSPITALS ENTER. L (APOLLOHOSP) and LINCOLN PHARMA LTD (LINCOLN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, APOLLO HOSPITALS ENTER. L leads APOLLOHOSP vs LINCOLN on 8 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

65.36
P/E ratio
13.61
13.42
P/B ratio
1.65
0.11%
Dividend yield
0.29%
₹135.04
EPS
₹43.88

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

22.10%
Return on equity
12.30%
18.00%
Return on capital
16.00%
15.00%
EBITDA margin
15.00%
7.94%
Net margin
13.11%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
9.58%
33.39%
Profit CAGR (3Y)
6.43%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.27L Cr
Market cap
₹1,197 Cr
₹25,228 Cr
Revenue
₹671 Cr
₹2,003 Cr
Net profit
₹88 Cr
0.90
Debt / equity
0.01
APOLLO HOSPITALS ENTER. L
  • + ["Company has delivered good profit growth of 77.8% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 17.7%"]
  • ["Stock is trading at 13.4 times its book value", "Company might be capitalizing the interest cost"]
LINCOLN PHARMA LTD
  • + ["Company is almost debt free."]
  • ["The company has delivered a poor sales growth of 9.61% over past five years.", "Company has a low return on equity of 13.8% over last 3 years.", "Earnings include an other income of Rs.33.4 Cr.", "Dividend payout has been low at 4.11% of profits over last 3 years", "Working capital days have increased from 159 days to 239 days"]
APOLLO HOSPITALS ENTER. L full analysis LINCOLN PHARMA LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.